FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225005429> ?p ?o ?g. }

• W4225005429 endingPage "13101" @default.
• W4225005429 startingPage "13095" @default.
• W4225005429 abstract "Colorectal cancer (CRC) is one of the major causes of cancer-linked mortality worldwide. Selective therapeutic approaches toward cancer are the need of the hour to combat cancer. Synthetic lethality is a pragmatic targeted cancer therapy in which cancer cell-specific vulnerabilities such as genetic defects/somatic mutations are exploited for selective cancer therapy by targeting genetic interactors (synthetic lethal interactors) of such mutation/defects present in cancer cells. In this study, we investigated the synthetic lethal interaction between checkpoint kinase 2 (CHEK2) and peroxiredoxin-2 (PRDX2) in CRC cells to precisely target CRC cells having CHEK2 defects. We have performed siRNA-mediated silencing and n-carbamoyl alanine (NCA)-mediated inhibition of PRDX2 in CHEK2-null HCT116 cells to confirm the synthetic lethal (SL) interaction between PRDX2 and CHEK2 as the cell population reduced significantly after silencing/inhibition of PRDX2. Additionally, treatment with NCA resulted in an increased level of total ROS in both cell types (HCT116 and CHEK2-null HCT116 cells), which further confirms that inhibition of PRDX2 results in an increased ROS level, which are mainly responsible for DNA double-strand breaks (DSBs). ROS-induced DNA DSBs get repaired in HCT116 cells, in which CHEK2 is in the normal functional state, but these DNA DSBs persist in CHEK2-null HCT116 cells as confirmed by the immunofluorescence analysis of 53BP1 and γ-H2AX. Finally, CHEK2-null HCT116 cells undergo apoptosis due to persistent DNA damage as confirmed by immunofluorescence analysis of cleaved caspase-3. The findings of this study suggest that PRDX2 has a SL interaction with CHEK2, and this interaction can be exploited for the targeted cancer therapy using NCA as a drug inhibitor of PRDX2 for the therapy of colorectal cancer having CHEK2 defects. Further studies are warranted to confirm the interaction in the preclinical model." @default.
• W4225005429 created "2022-04-29" @default.
• W4225005429 creator A5015597377 @default.
• W4225005429 creator A5025111910 @default.
• W4225005429 creator A5036589842 @default.
• W4225005429 creator A5049952200 @default.
• W4225005429 creator A5050167205 @default.
• W4225005429 creator A5063583565 @default.
• W4225005429 creator A5087423546 @default.
• W4225005429 date "2022-04-04" @default.
• W4225005429 modified "2023-09-28" @default.
• W4225005429 title "<i>N</i>-Carbamoyl Alanine-Mediated Selective Targeting for CHEK2-Null Colorectal Cancer" @default.
• W4225005429 cites W1544851750 @default.
• W4225005429 cites W1973268287 @default.
• W4225005429 cites W1984528393 @default.
• W4225005429 cites W1991601855 @default.
• W4225005429 cites W2003438913 @default.
• W4225005429 cites W2009007206 @default.
• W4225005429 cites W2042376976 @default.
• W4225005429 cites W2044387885 @default.
• W4225005429 cites W2067427915 @default.
• W4225005429 cites W2071289226 @default.
• W4225005429 cites W2088720735 @default.
• W4225005429 cites W2110017381 @default.
• W4225005429 cites W2110152791 @default.
• W4225005429 cites W2114843025 @default.
• W4225005429 cites W2124156743 @default.
• W4225005429 cites W2180814331 @default.
• W4225005429 cites W2262414037 @default.
• W4225005429 cites W2325707043 @default.
• W4225005429 cites W2337885453 @default.
• W4225005429 cites W2583869923 @default.
• W4225005429 cites W2594373254 @default.
• W4225005429 cites W2620241325 @default.
• W4225005429 cites W2889646458 @default.
• W4225005429 cites W2969587905 @default.
• W4225005429 cites W2996770601 @default.
• W4225005429 cites W3009963727 @default.
• W4225005429 cites W3012444892 @default.
• W4225005429 cites W3032979845 @default.
• W4225005429 cites W3093265161 @default.
• W4225005429 cites W3170609854 @default.
• W4225005429 doi "https://doi.org/10.1021/acsomega.2c00527" @default.
• W4225005429 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35474765" @default.
• W4225005429 hasPublicationYear "2022" @default.
• W4225005429 type Work @default.
• W4225005429 citedByCount "2" @default.
• W4225005429 countsByYear W42250054292022 @default.
• W4225005429 countsByYear W42250054292023 @default.
• W4225005429 crossrefType "journal-article" @default.
• W4225005429 hasAuthorship W4225005429A5015597377 @default.
• W4225005429 hasAuthorship W4225005429A5025111910 @default.
• W4225005429 hasAuthorship W4225005429A5036589842 @default.
• W4225005429 hasAuthorship W4225005429A5049952200 @default.
• W4225005429 hasAuthorship W4225005429A5050167205 @default.
• W4225005429 hasAuthorship W4225005429A5063583565 @default.
• W4225005429 hasAuthorship W4225005429A5087423546 @default.
• W4225005429 hasBestOaLocation W42250054292 @default.
• W4225005429 hasConcept C104317684 @default.
• W4225005429 hasConcept C119056186 @default.
• W4225005429 hasConcept C121608353 @default.
• W4225005429 hasConcept C134935766 @default.
• W4225005429 hasConcept C13514818 @default.
• W4225005429 hasConcept C143425029 @default.
• W4225005429 hasConcept C153911025 @default.
• W4225005429 hasConcept C185592680 @default.
• W4225005429 hasConcept C190283241 @default.
• W4225005429 hasConcept C2776071976 @default.
• W4225005429 hasConcept C501734568 @default.
• W4225005429 hasConcept C502942594 @default.
• W4225005429 hasConcept C54355233 @default.
• W4225005429 hasConcept C552990157 @default.
• W4225005429 hasConcept C86803240 @default.
• W4225005429 hasConcept C96232424 @default.
• W4225005429 hasConceptScore W4225005429C104317684 @default.
• W4225005429 hasConceptScore W4225005429C119056186 @default.
• W4225005429 hasConceptScore W4225005429C121608353 @default.
• W4225005429 hasConceptScore W4225005429C134935766 @default.
• W4225005429 hasConceptScore W4225005429C13514818 @default.
• W4225005429 hasConceptScore W4225005429C143425029 @default.
• W4225005429 hasConceptScore W4225005429C153911025 @default.
• W4225005429 hasConceptScore W4225005429C185592680 @default.
• W4225005429 hasConceptScore W4225005429C190283241 @default.
• W4225005429 hasConceptScore W4225005429C2776071976 @default.
• W4225005429 hasConceptScore W4225005429C501734568 @default.
• W4225005429 hasConceptScore W4225005429C502942594 @default.
• W4225005429 hasConceptScore W4225005429C54355233 @default.
• W4225005429 hasConceptScore W4225005429C552990157 @default.
• W4225005429 hasConceptScore W4225005429C86803240 @default.
• W4225005429 hasConceptScore W4225005429C96232424 @default.
• W4225005429 hasFunder F4320321145 @default.
• W4225005429 hasIssue "15" @default.
• W4225005429 hasLocation W42250054291 @default.
• W4225005429 hasLocation W42250054292 @default.
• W4225005429 hasLocation W42250054293 @default.
• W4225005429 hasOpenAccess W4225005429 @default.
• W4225005429 hasPrimaryLocation W42250054291 @default.
• W4225005429 hasRelatedWork W2042520059 @default.

• next